Quest's Q1 Revenues Fall 6 Percent as It Misses Estimates on Top and Bottom Line | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that its revenues in the first quarter dropped 6 percent year over year as it missed the average analyst estimate on both the top and bottom lines.

For the three months ended March 31, the firm brought in $1.79 billion in revenues, down from $1.91 billion a year ago and short of the $1.86 billion expected by Wall Street.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.